Show simple item record

AuthorKarim, Nagi
AuthorHabib, Abdella M.
Available date2021-03-25T06:31:16Z
Publication Date2021-07-31
Publication NameCellular Signalling
Identifierhttp://dx.doi.org/10.1016/j.cellsig.2021.109976
CitationNagi K, Habib AM. Biased signaling: A viable strategy to drug ghrelin receptors for the treatment of obesity. Cell Signal. 2021 Mar 10;83:109976. doi: 10.1016/j.cellsig.2021.109976.
ISSN08986568
URIhttps://www.sciencedirect.com/science/article/pii/S0898656821000644
URIhttp://hdl.handle.net/10576/17969
AbstractObesity is a global burden and a chronic ailment with damaging overall health effects. Ghrelin, an octanoylated 28 amino acid peptide hormone, is secreted from the oxyntic mucosa of the stomach. Ghrelin acts on regions of the hypothalamus to regulate feeding behavior and glucose homeostasis through its G protein-coupled receptor. Recently, several central pathways modulating the metabolic actions of ghrelin have been reported. While these signaling pathways can be inhibited or activated by antagonists or agonists, they can also be discriminatingly activated in a “biased” response to impart different degrees of activation in distinct pathways downstream of the receptor. Here, we review recent ghrelin biased signaling findings as well as characteristics of ghrelin hormone and its receptors pertinent for biased signaling. We then evaluate the feasibility for ghrelin receptor biased signaling as a strategy for the development of effective pharmacotherapy in obesity treatment.
Languageen
PublisherElsevier
SubjectBias
Ghrelin
Biased agonism
Obesity
Dimer
Functional selectivity
TitleBiased signaling: A viable strategy to drug ghrelin receptors for the treatment of obesity
TypeArticle
Volume Number83
Open Access user License http://creativecommons.org/licenses/by/4.0/


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record